Bicocca Open Archive

Logo unimib boa
DI FRANCESCO, JACOPO COSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.652
AS - Asia 5.075
EU - Europa 4.813
SA - Sud America 811
Continente sconosciuto - Info sul continente non disponibili 780
AF - Africa 140
OC - Oceania 10
Totale 21.281
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.176
SG - Singapore 1.739
IT - Italia 1.521
CN - Cina 1.129
DE - Germania 781
BR - Brasile 609
VN - Vietnam 605
RU - Federazione Russa 559
HK - Hong Kong 557
SE - Svezia 406
CA - Canada 354
IE - Irlanda 295
GB - Regno Unito 281
BD - Bangladesh 261
FI - Finlandia 194
FR - Francia 185
IN - India 181
UA - Ucraina 181
TR - Turchia 80
AT - Austria 78
IQ - Iraq 75
AR - Argentina 73
MX - Messico 60
ID - Indonesia 58
JP - Giappone 58
ES - Italia 55
ZA - Sudafrica 53
NL - Olanda 52
KR - Corea 49
PL - Polonia 45
PK - Pakistan 41
DK - Danimarca 37
BE - Belgio 35
EC - Ecuador 30
PH - Filippine 30
UZ - Uzbekistan 28
CH - Svizzera 27
CO - Colombia 26
SA - Arabia Saudita 25
CL - Cile 23
AE - Emirati Arabi Uniti 22
VE - Venezuela 21
MA - Marocco 20
MY - Malesia 18
IR - Iran 15
CR - Costa Rica 13
EG - Egitto 10
LB - Libano 10
PT - Portogallo 10
PY - Paraguay 10
AZ - Azerbaigian 9
HU - Ungheria 9
KE - Kenya 9
PS - Palestinian Territory 9
LT - Lituania 8
NI - Nicaragua 8
OM - Oman 8
PE - Perù 8
RO - Romania 8
TN - Tunisia 8
AU - Australia 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
EU - Europa 7
GE - Georgia 7
GR - Grecia 7
JO - Giordania 7
KZ - Kazakistan 7
NP - Nepal 7
PA - Panama 7
TH - Thailandia 7
AL - Albania 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
HN - Honduras 6
JM - Giamaica 6
KW - Kuwait 6
NG - Nigeria 6
BA - Bosnia-Erzegovina 5
BH - Bahrain 5
BO - Bolivia 5
GT - Guatemala 5
IL - Israele 5
MD - Moldavia 4
NO - Norvegia 4
UY - Uruguay 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
KG - Kirghizistan 3
LK - Sri Lanka 3
MN - Mongolia 3
QA - Qatar 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
EE - Estonia 2
LY - Libia 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
Totale 20.477
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.681
Singapore 1.093
Ashburn 821
San Jose 549
Hong Kong 547
Milan 503
Chandler 418
Fairfield 414
Frankfurt am Main 412
Woodbridge 405
Wilmington 388
Houston 288
Dublin 286
New York 260
Santa Clara 246
Toronto 219
Los Angeles 203
Beijing 189
Seattle 184
Jacksonville 180
Munich 179
Dearborn 173
Ho Chi Minh City 168
Cambridge 142
Council Bluffs 140
Hanoi 131
Dallas 128
Chicago 126
Rome 126
Princeton 122
Helsinki 120
The Dalles 101
Nanjing 88
Buffalo 76
São Paulo 74
Shanghai 71
Hefei 68
Lauterbourg 64
Vienna 61
Moscow 58
Boardman 53
Columbus 53
Orem 50
Lawrence 49
Seoul 42
Altamura 39
Brooklyn 38
Dong Ket 37
Jakarta 37
Tokyo 37
London 35
Baghdad 34
Denver 32
Da Nang 31
Guangzhou 31
Lachine 31
Montreal 31
Johannesburg 30
Nuremberg 28
Tashkent 28
Brussels 27
Warsaw 26
Atlanta 25
Boston 25
Sesto San Giovanni 25
Chennai 24
Figino 24
Jinan 23
Ottawa 23
Rio de Janeiro 23
San Diego 23
Andover 22
Bologna 22
Monza 22
Pune 22
Grafing 21
Turin 21
Florence 20
Nanchang 20
Changsha 19
Fremont 19
Phoenix 19
Ankara 18
Haiphong 18
Santiago 18
Stockholm 18
Zhengzhou 18
Manchester 17
Shenyang 17
Hangzhou 16
Poplar 16
Tianjin 16
Amsterdam 15
Mexico City 15
San Francisco 15
Turku 15
Dhaka 14
Istanbul 14
Kocaeli 14
Zurich 14
Totale 13.031
Salva come PNG Salva come JPEG
Nome #
Anti-Aβ autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies 529
Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation 528
Cardiac and neuronal HCN channelopathies 496
TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy 474
Effect of the ketogenic diet in excitable tissues 448
Clinical, biological and neuroradiological evolution of Cerebral Amyloid Angiopathy-related inflammation: the iCAβ International Network longitudinal study. 425
Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy 418
HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature 413
Implementation of continuous qEEG in two neurointensive care units by intensivists: a feasibility study 383
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy 380
Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease 379
Progressive epileptic encephalopathy associated with a novel HCN2 mutation 376
Long-term applicability of the new ILAE definition of epilepsy. Results from the PRO-LONG study 364
Temporal lobe dysfunction in late-onset epilepsy of unknown origin 360
Generation and validation of algorithms to identify subjects with dementia using administrative data 359
Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis 345
A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet 334
Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics 333
Do the functional properties of HCN1 mutants correlate with the clinical features in epileptic patients? 332
Valproate induces epigenetic modifications in lymphomonocytes from epileptic patients 318
Cerebral Amyloid Angiopathy-Related Inflammation 310
Prodromal Alzheimer's Disease Presenting as Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Amyloid-Related Imaging Abnormalities and High Cerebrospinal Fluid Anti-Aβ Autoantibodies 309
Novel neurofibromatosis type 2 mutation presenting with status epilepticus 308
Immune-mediated mechanisms in the pathogenesis of cerebral amyloid angiopathy-related inflammation and Alzheimer's disease: Role of anti-A beta auto-antibodies 304
Brain targets: can you believe your own eyes? 299
Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on long-term outcome 299
Cerebellar hematoma in a carrier of the A3243G MELAS mutation 296
Valproate and HDAC inhibition: A new epigenetic strategy to mitigate phenotypic severity in ALS? 277
Perampanel in Brain Tumor-Related Epilepsy: A Systematic Review 272
Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation 271
HCN1 novel mutations in familiar generalized epilepsy 269
Long-term risk of chronic epilepsy in adults after post-anoxic coma and refractory status epilepticus: A retrospective cohort study 268
The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study 266
Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case report 262
COVID‐19‐associated immune‐mediated encephalitis mimicking acute‐onset Creutzfeldt‐Jakob disease 262
Validation of Clinical-Radiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-related Inflammation 260
A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine 259
A case of Leber hereditary optic neuropathy plus dystonia caused by G14459A mitochondrial mutation 257
Huntington's disease and HDACi: Would sulpiride and valproate be of therapeutic value? 254
HCN1 mutation spectrum: From neonatal epileptic encephalopathy to benign generalized epilepsy and beyond 249
Neurological soft signs are increased in migraine without aura: relationship with the affective status 248
Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-Aβ Autoantibodies 248
Epilepsy in Cerebral Amyloid Angiopathy: an observational retrospective study of a large population 242
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 242
Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes 241
Cerebral amyloid angiopathy-related inflammation: an emerging disease 239
MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines 237
Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project 237
Anti-Abeta autoantibodies in cerebral amyloid angiopathy related inflammation: a role for pathogenesis? 235
Epilptic seizures and psychogenic non-epileptic seizures 233
Efficacy and tolerability of low versus standard daily doses of antiseizure medications in newly diagnosed focal epilepsy. A multicenter, randomized, single-blind, non-inferiority trial (STANDLOW) 229
Recurrence of Cerebral Amyloid Angiopathy-Related Inflammation: A Report of Two Cases from the iCAβ International Network 229
Autoimmune encephalopathy in Graves' disease: Remission after total thyroidectomy 217
Anti-Aß autoantibodies in cerebral amyloid angiopathy-related inflammation: a human spontaneous model of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease 215
Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study 213
A novel de novo HCN1 loss-of-function mutation in genetic generalized epilepsy causing increased neuronal excitability 213
A loss-of-function HCN4 mutation associated with familial benign myoclonic epilepsy in infancy causes increased neuronal excitability 208
Immune-mediated mechanisms in the pathogenesis of cerebral amyloid angiopathy-related inflammation and Alzheimer's disease: Role of anti-Aβ auto-antibodie 200
A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study 199
Cerebral Amyloid Angiopathy-Related Inflammation: Report of a Case with Very Difficult Therapeutic Management 194
Perampanel in post-stroke epilepsy: Clinical practice data from the PERampanel as Only Concomitant antiseizure medication (PEROC) study 191
Complicanze neurologiche di malattie internistiche 189
Recessive loss-of-function mutation in the pacemaker HCN2 channel causing increased neuronal excitability in a patient with idiopathic generalized epilepsy 189
The management of epilepsy in clinical practice: Do the timing and severity of the disease influence the priorities of patients and the caring physicians? Data from the EPINEEDS study 186
Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy 180
LATE-ONSET EPILEPSY WITH UNKNOWN ETIOLOGY: A PILOT STUDY ON NEUROPSYCHOLOGICAL PROFILE, CEREBROSPINAL FLUID BIOMARKERS, AND QUANTITATIVE EEG CHARACTERISTICS 178
Anti-AB autoantibodies and endothelial damage during amyloid-related imaging abnormalities (ARIA): report from the Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's disease Biomarkers Collaborative Network 175
CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy 146
Management of epilepsy in older adults: A critical review by the ILAE Task Force on Epilepsy in the elderly 115
Iatrogenic Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Case Series 110
Compound Heterozygous PNKP Variants Causing Developmental and Epileptic Encephalopathy with Severe Microcephaly: Natural History of Two New Cases and Literature Review 100
The epidemiology of epilepsy in older adults: A narrative review by the ILAE Task Force on Epilepsy in the Elderly 70
Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes 66
Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP2-Dependent K+ Channel Gating 62
The hidden link between late-onset seizures and cerebral amyloid angiopathy: A case–control study 61
Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: Novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study 58
Determinants of cerebral amyloid angiopathy progression: a multicenter retrospective study 53
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy 53
Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) 53
Effectiveness of perampanel as the only add-on: Retrospective, multicenter, observational real-life study on epilepsy patients 53
Effectiveness of perampanel as only concomitant antiseizure medication for highly active epilepsy: insight from a real-world, multicenter retrospective study 50
Etiological diagnosis of late-onset epilepsy: A key priority for Italian epileptologists – Insights from a LICE survey 45
Iatrogenic cerebral amyloid angiopathy: A multinational case series and individual patient data analysis of the literature 42
Pharmacological approaches in drug-resistant pediatric epilepsies caused by pathogenic variants in potassium channel genes 39
Clinical-radiological presentation and natural history of iatrogenic cerebral amyloid angiopathy 38
Iatrogenic cerebral amyloid angiopathy after red blood cell transfusion? 38
Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach 38
Case report: Marked electroclinical improvement by fluoxetine treatment in a patient with KCNT1-related drug-resistant focal epilepsy 37
Adjunctive Brivaracetam in People with Epilepsy and Intellectual Disability: Evidence from the BRIVAracetam Add-On First Italian netwoRk Study 37
Cerebrospinal Fluid β-Amyloid and τ Levels in Patients With Iatrogenic Cerebral Amyloid Angiopathy, Sporadic Cerebral Amyloid Angiopathy, Alzheimer Disease, and Controls 36
Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy 35
Dysfunctional HCN ion channels in neurological diseases 34
Perampanel as only add-on epilepsy treatment in elderly: A subgroup analysis of real-world data from retrospective, multicenter, observational study 32
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures 29
Long-term analysis of the effects of COVID-19 in people with epilepsy: Results from a multicenter on-line survey across the pandemic waves 29
Impaired occipital cerebrovascular reactivity as a biomarker for vascular β-amyloid 28
Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study 28
Early Parkinsonism in a Senegalese girl with Lafora disease 27
Relevance of clinical context in the diagnostic-therapeutic approach to status epilepticus 26
Alternating Hemiplegia and Epilepsia Partialis Continua: A new phenotype for a novel compound TBC1D24 mutation 26
Totale 21.046
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022974 0 125 127 95 92 102 40 47 52 50 83 161
2022/20231.767 173 493 166 193 130 246 35 86 171 12 27 35
2023/20241.090 28 66 49 73 156 262 168 59 78 13 19 119
2024/20252.872 137 291 164 101 231 187 270 156 312 423 225 375
2025/20268.597 798 344 525 898 921 349 1.024 678 703 926 568 863
2026/2027585 379 206 0 0 0 0 0 0 0 0 0 0
Totale 21.281